1478-811X-7-14 1478-811X Review <p>Expression and function of the insulin receptor substrate proteins in cancer</p> Mardilovich Katerina katerina.mardilovich@umassmed.edu Pankratz L Shannon shannon.pankratz@umassmed.edu Shaw M Leslie leslie.shaw@umassmed.edu

Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA

 Cell Communication and Signaling 1478-811X 2009 7 1 14 http://www.biosignaling.com/content/7/1/14 19534786 10.1186/1478-811X-7-14 03 5 2009 17 6 2009 17 6 2009 2009 Mardilovich et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The Insulin Receptor Substrate (IRS) proteins are cytoplasmic adaptor proteins that function as essential signaling intermediates downstream of activated cell surface receptors, many of which have been implicated in cancer. The IRS proteins do not contain any intrinsic kinase activity, but rather serve as scaffolds to organize signaling complexes and initiate intracellular signaling pathways. As common intermediates of multiple receptors that can influence tumor progression, the IRS proteins are positioned to play a pivotal role in regulating the response of tumor cells to many different microenvironmental stimuli. Limited studies on IRS expression in human tumors and studies on IRS function in human tumor cell lines and in mouse models have provided clues to the potential function of these adaptor proteins in human cancer. A general theme arises from these studies; IRS-1 and IRS-4 are most often associated with tumor growth and proliferation and IRS-2 is most often associated with tumor motility and invasion. In this review, we discuss the mechanisms by which IRS expression and function are regulated and how the IRS proteins contribute to tumor initiation and progression.

Introduction

The Insulin Receptor Substrate (IRS) proteins are a family of cytoplasmic adaptor proteins that were first identified for their role in insulin signaling. The first family member to be identified, IRS-1, was initially characterized as a 185 kD phosphoprotein that was detected in anti-phosphotyrosine immunoblots in response to insulin stimulation 1. IRS-2 was discovered as an alternative insulin receptor substrate, initially named 4PS, in insulin-stimulated cells derived from Irs-1-/- mice 2. IRS-1 and IRS-2 are ubiquitously expressed and are the primary mediators of insulin-dependent mitogenesis and regulation of glucose metabolism in most cell types (reviewed in 3). Humans express one additional family member, IRS-4, which is more restricted in its expression pattern and is found primarily in brain, kidney, thymus and liver 4. A fourth IRS protein, Irs-3, is expressed in rodents, but not in humans 56. More distantly related IRS family members IRS-5 and IRS-6, also known as DOK4 and DOK5, share homology in their N-termini, but have truncated C-termini 789 (Figure 1). Despite their significant homology, it is clear from the genotypes of knockout mice that the IRS proteins have non-redundant normal functions. Irs-1-/- mice are born small and remain runted throughout their lives, implicating a role for this IRS protein in somatic growth regulation 1011. A similar contribution of the IRS homolog Chico to the regulation of cell size and growth in Drosophila has been observed 12. Mice deficient for Irs-1 develop insulin resistance but do not progress to diabetes because they maintain normal pancreatic β-cell numbers. Irs-2-/- mice are normal in size but have brain defects, the result of a 50% decrease in neuronal proliferation 1314. In contrast to Irs-1-/- mice, Irs-2-deficient mice develop early-onset diabetes due to a combination of peripheral insulin resistance and a loss of β-cell function 1315. Irs-2-/- females are also infertile, which together with evidence from insulin-signaling in Drosophila and C. elegans, supports a conserved mechanism for integrating reproduction and metabolism 16. Irs-4-/- mice are phenotypically normal, with only mild growth, reproductive and insulin sensitivity defects 17. These differences in IRS function in normal development and physiology are also evident in cancer.

<p>Figure 1</p>

Schematic of the IRS protein family

Schematic of the IRS protein family. Interaction domains of the IRS proteins are indicated. PH (purple), pleckstrin homology domain; PTB (purple), phosphotyrosine binding domain; KRLB (pink), kinase regulatory loop binding domain; PI3K (orange), region containing multiple PI3K binding motifs; Grb-2 (green), Grb-2 binding site; SHP-2 (yellow), SHP-2 binding site. IRS-5 and IRS-6 contain regions of similarity to each other in their C-termini (light purple).

The IRS proteins contain no intrinsic enzymatic activity and they contribute to signaling through their function as adaptors to organize signaling complexes 18. They share their highest level of homology in their N-termini, which contain two highly conserved domains that contribute to their recruitment to activated upstream receptors. The first of these domains is the pleckstrin homology (PH) domain. The PH domain is hypothesized to mediate both protein-protein interactions that facilitate the recruitment of the IRS proteins to receptors, and protein-phospholipid interactions that localize the IRS proteins to the cell membrane, in close proximity to transmembrane receptors 192021. The second conserved region is the phosphotyrosine binding (PTB) domain, which interacts with NPXY motifs in activated receptors 2223. An additional motif that contributes to receptor recruitment, the kinase regulatory loop binding (KRLB) domain, has been identified only in IRS-2 (Fig. 1)2224. Upon binding to upstream receptors, the IRS proteins are phosphorylated on tyrosine residues in their C-termini, generating binding sites that recruit downstream effectors 2526. Effectors that have been characterized to bind to the IRS proteins include PI3K, Grb-2, SHP-2, Fyn, c-Crk, CrkII and Nck 9272829303132. A recent study that utilized phosphorylated bait peptides to profile all potential phosphotyrosine dependent interaction sites in IRS-1 and IRS-2 identified additional potential interacting proteins 33. However, additional studies will be necessary to determine if these effectors are recruited to the intact IRS proteins in response to physiological stimuli. It is the combined action of the downstream effectors that determine the signals that are transmitted through the IRS proteins and the cellular response that occurs (Figure 2). Importantly, many of these effector-signaling pathways have been implicated in tumorigenesis and cancer progression.

<p>Figure 2</p>

Signaling via the IRS proteins

Signaling via the IRS proteins. The IRS proteins are recruited to activated cell surface receptors via PH/PTB domains in their N-termini. Once bound, they are phosphorylated on tyrosine residues in their C-termini. The phosphorylation of tyrosine residues (pY) creates docking sites for the recruitment of downstream signaling effectors. Subsequently, signaling cascades are activated that can regulate gene expression, protein synthesis, glycolysis, cell proliferation, survival and motility/invasion.

Expression of the IRS proteins in human cancer

There are relatively few reports on the expression patterns of the IRS adaptor proteins in human tumors, either at the mRNA or protein level. The majority of these studies have evaluated the expression of IRS-1 and IRS-2, which are the more ubiquitously expressed family members in normal tissue. As an overall summary, IRS expression is most often elevated in human tumors when compared with normal tissue (Table 1). Expression of both IRS-1 and IRS-2 is reported to be increased in hepatocellular, pancreatic and prostate cancer and malignant pleural mesothelioma 34353637383940. In other cancers, including breast, ovarian and medulloblastoma, only IRS-1 expression has been evaluated and a similar trend toward increased expression in primary tumors has been reported 41424344. However, in breast cancer, which has been studied the most extensively of all cancers for IRS expression, there is also evidence that the expression of IRS-1 could correlate negatively with tumor progression. Specifically, IRS-1 is expressed at moderate to strong levels in normal tissue and well-differentiated carcinomas, but expression decreases in more poorly differentiated, higher-grade tumors 4546. Decreased IRS-1 expression is also observed in some non-small cell lung cancers (NSCLC), and this lower expression occurs more frequently in squamous cell carcinomas 47. The conclusion drawn from the lung cancer study was that downregulation of IRS-1 may be an early event in NSCLC development. To date, the only study to examine IRS-4 expression in human cancer reported increased expression in hepatocellular carcinoma 39. Finally, both IRS-2 and IRS-5 are upregulated at the level of gene expression in clear cell renal cell carcinoma 48. One caveat to all of these expression studies, however, is that the IRS proteins can be phosphorylated on serine residues through negative feedback loops, which inhibits their function (reviewed in 49). Therefore, expression of the IRS proteins may not reflect the functional status of these adaptor proteins. Additional studies are needed to establish clearly the expression and function of the IRS proteins in human cancer and to determine if their relative expression levels have prognostic or predictive value.

<p>Table 1</p>

IRS expression in human cancer

Cancer Type

IRS

Expression

Notes

Ref(s)

Breast

↑ IRS-1

Well differentiated primary tumors

41 43

↑ IRS-1

Nuclear IRS-1 correlates with good prognosis

46

↓ IRS-1

Poorly differentiated, high grade tumors

45 46

Hepatocellular

↑ IRS-1

mRNA/protein increased in HCC

38 39

↑ IRS-2

mRNA/protein increased in HCC

38 39

↑ IRS-4

mRNA increased in HCC

39

Lung

↓ IRS-1

Larger (stage 1B) tumors, squamous cell carcinoma

47

Medulloblastoma

↑ IRS-1

Co-localized with polyoma JCV T-antigen in nucleus

42

Mesothelioma

↑ IRS-1

mRNA increased in malignant pleural mesothelioma

37

↑ IRS-2

mRNA increased in malignant pleural mesothelioma

37

Ovarian

↑ IRS-1

Protein increased in malignant epithelial tumors

44

Pancreatic

↑ IRS-1

mRNA increased in 7/16 tumors

34

↑ IRS-2

mRNA/protein increased in ductal-like cancer cells

35

Prostate

↑ IRS-1

Protein increased in tumors and metastases

36

↑ IRS-2

Protein correlates with increased Myc expression

40

Renal

↑ IRS-2

mRNA increased in clear cell carcinomas

48

↑ IRS-5

mRNA increased in clear cell carcinomas

48

Upstream receptors implicated in cancer

The IRS proteins function as essential signaling intermediates downstream of many cell surface receptors that have been implicated in cancer. For example, the IRS proteins are major downstream effectors of the Insulin-Like Growth Factor-1 (IGF-1) receptor (IGF-1R) and they play a critical role in determining the cellular response to IGF-1 stimulation 50. There is a strong correlation between enhanced IGF-1-mediated signaling and a wide range of cancers including malignancies of the breast, colon, prostate, thyroid, liver, pancreas and central nervous system 51. In breast cancer, IGF-1 expression is elevated in the serum of patients and the IGF-1R is frequently over-expressed and is a prognostic indicator of tumor recurrence and reduced patient survival 5253. Other growth factor/hormone receptors that signal through the IRS proteins and that are associated with cancer include the insulin, prolactin, growth hormone (GH), and vascular endothelial growth factor (VEGF; KDR) receptors 545556. The IRS proteins have also been implicated in signaling downstream of the EGF receptor (EGFR), which may involve an EGFR/IGF-1R cross-talk 5758. Some integrin adhesion receptors also utilize the IRS proteins as signaling intermediates to relay intracellular signals 596061. In addition to surface receptors, several oncogenic fusion proteins that arise as the result of chromosomal translocations have also been reported to signal through the IRS adaptor proteins for their tumor promoting functions. These include the ETV6-NTRK3 gene fusion found in pediatric spindle cell sarcomas and secretory breast cancer, the RET-PTC3 gene fusion found in papillary thyroid cancer and the NPM-ALK gene fusion that is a transforming oncogene found in anaplastic large-cell lymphoma 626364. Full length anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily and receptor for the growth factor pleiotrophin, also signals through the IRS proteins. ALK is expressed in breast and pancreatic carcinomas, melanoma and neuroblastoma, and has been demonstrated to be rate limiting for glioblastoma growth 65. As common intermediates of many receptors that can influence tumor progression, the IRS proteins are positioned to play a key role in regulating the response of tumor cells to microenvironmental stimuli. As a result, they are also attractive candidates to be targets for interfering with the tumor-promoting signals that are initiated through these disparate receptors.

IRS function in cancer

There are many studies on IRS function in human tumor cell lines and in mouse models that provide clues to the potential function of these adaptor proteins in human cancer. A general theme arises from these studies; IRS-1 and IRS-4 are most often associated with tumor growth and proliferation and IRS-2 is most often associated with tumor motility and invasion.

IRS-1

IRS-1 involvement in regulating tumor cell proliferation was foreshadowed by its role in somatic growth regulation. IRS-1 null mice are approximately 30% smaller than wildtype littermates and they maintain their runted phenotype throughout life 1011. IRS-1 is the predominant IRS family member that is activated by IGF-1 in well-differentiated estrogen receptor positive (ER+) human breast carcinoma cell lines 6667. IRS-1 mediates IGF-1-dependent growth in these cells, which has also been observed for hepatocellular and prostate carcinoma, medulloblastoma and malignant pleural mesothelioma cell lines 376667686970. The activation of both MAPK and PI3K signaling pathways has been implicated in the stimulation of proliferation by IRS-1 67697172. IRS-1-dependent signals also contribute to tumor cell survival. Suppression of IRS-1 expression by siRNA promotes apoptosis and renders ER+ breast carcinoma cells more sensitive to tamoxifen-stimulated cell death, whereas overexpression of IRS-1 confers resistance to TGF-β-induced cell death in hepatocellular carcinoma cells 7374. In contrast, Irs-1-/- mammary tumor cells derived from mouse mammary tumor virus (MMTV)-polyoma virus middle T antigen (PyV-MT) mice are more resistant to apoptosis in response to serum deprivation than wildtype cells 75.

Transgenic mouse models have provided important information regarding IRS-1 function in cancer. Overexpression of IRS-1 in the mouse mammary gland results in mammary hyperplasia and tumorigenesis, which correlates with constitutive tyrosine phosphorylation of IRS-1, activation of Akt and Erk1/2 and association with β-catenin 76. In mouse hepatocytes, overexpression of IRS-1 increases DNA synthesis and hepatic mass by 25%, further supporting the connection between IRS-1 and proliferation 77. However, liver tumors do not develop in these transgenic mice, possibly because Fas-receptor is upregulated and this pro-apoptotic signal balances the pro-growth signals from IRS-1 78. The different results of these transgenic models with regard to tumorigenesis suggest that the oncogenic potential of IRS-1 may be dependent upon cellular context. Although IRS-1 overexpression promotes tumorigenesis, IRS-1 is not required for primary tumor growth as demonstrated by the fact that mammary tumor initiation and growth are not prevented or delayed in Irs-1-/- mice in response to the PyV-MT antigen when compared with tumors that develop in wildtype littermates 79. One important caveat to the IRS overexpression and knockout mouse mammary tumor studies is that the tumors that develop in both models are ER- and a possible preferential role for IRS-1 in ER+ tumor growth, which is suggested from the studies on human breast carcinoma cell lines, cannot be excluded. In contrast with the positive role for IRS-1 in early tumor development and growth, IRS-1 may play a suppressive role in tumor progression. Specifically, PyV-MT:Irs-1-/- mammary tumors have a greater incidence and rate of lung metastasis when compared with PyV-MT:WT tumors 7980. Together with the IRS-1 expression data in human breast and lung cancer, these results reveal that loss of IRS-1 expression or function may facilitate tumor progression 454647. Once again, however, it is likely that IRS-1 function is cell context-dependent because deletion of Irs-1 in Apcmin-/+(Min)/β-catenin-derived intestinal tumors decreases tumor incidence and growth and increases irradiation-induced apoptosis in the intestinal crypt 81.

IRS-2

The association of IRS-2 with tumor progression was first indicated by the finding that inhibition of the IGF-1R in ER- breast carcinoma cells, which express IRS-2 and lack or have decreased IRS-1 expression, does not inhibit tumor proliferation. However, inhibition of IGF-1R function does prevent metastasis of these cells in xenograft models 8283. Several studies have since demonstrated that IGF-1 promotes cell motility and invasion in human breast carcinoma cell lines and mouse mammary tumor cells that signal preferentially through IRS-2, but not in cell lines that express only IRS-1 70848586. A similar role for IRS-2-dependent signaling in cell motility and invasion has been reported for neuroblastoma and mesothelioma cells 3787. In contrast to IRS-2, IRS-1 may suppress cell migration because expression of IRS-1 in LnCAP prostate carcinoma cells decreases their motility. One possible mechanism by which IRS-2 contributes to tumor progression and cell invasion is by positively regulating aerobic glycolysis via the enhanced localization of the GLUT-1 glucose transporter on the tumor cell surface 88. Similar to IRS-1, IRS-2 has also been implicated in promoting tumor cell survival, which is likely to contribute to its role in tumor progression. Irs-2-deficient PyV-MT-derived mammary tumor cells are significantly more sensitive to serum deprivation-induced apoptosis than wildtype tumor cells, and Irs-2-/- tumors also have a higher in situ level of apoptosis 75. Suppression of IRS-2 expression in hepatocellular carcinoma cells that express high levels of this adaptor protein also results in apoptosis 38. Recent studies in pancreatic adenocarcinoma cells reveal that IRS-2 can regulate the expression of the IGF-1R to sustain high levels of IGF-1-dependent signaling 89. Therefore, IRS-2 may promote tumor progression by stimulating a positive feedback loop to enhance IGF-1 signaling.

Additional support for IRS-2 as a positive regulator of tumor progression comes from in vivo mouse model studies. Mammary tumor metastasis is significantly diminished in PyV-MT:Irs-2-/- mice, and Irs-1 deficient tumors that express elevated levels of active (i.e. tyrosine phosphorylated) Irs-2 have enhanced metastatic rates 7579. Irs-2 expression is elevated in tumors that arise in PTEN+/- mice, and deletion of Irs-2 has no impact on tumor initiation, but it does suppress tumor growth and progression to invasive disease 40. IRS-2, like IRS-1, can promote tumor initiation and progression when this adaptor protein is overexpressed in the mammary gland, a finding that would appear to conflict with the inability of IRS-2 to regulate tumor proliferation in human breast carcinoma cell lines 7076. One possible explanation for this discrepancy is that functions that are not observed at normal expression levels are gained when IRS expression levels are elevated. Alternatively, IRS-1 and IRS-2 may contribute to early tumorigenesis through distinct mechanisms. That is, IRS-1 may promote enhanced proliferation, whereas IRS-2 may promote enhanced survival, with the common outcome being tumorigenesis and progression.

The differential abilities of IRS-1 and IRS-2 to promote proliferation and motility/invasion, respectively, raises the question of how these similar proteins regulate divergent functions. IRS-1 and IRS-2 share approximately 35% identity in their C-termini where they recruit downstream effectors to phosphotyrosine binding motifs to initiate their signaling cascades. Many of the motifs are conserved between the two family members, and IRS-1 and IRS-2 have been reported to activate common signaling pathways including PI3K and the Erk1/2 MAPK kinases in a variety of cancer model systems 2960699091. Both of these signaling pathways have been implicated in promoting tumor cell proliferation, invasion and survival, but they cannot explain the differential abilities of IRS-1 and IRS-2 to regulate these functions. One potential mechanism for IRS-specific regulation of tumor cell functions is the recruitment of effectors to unique binding motifs in the C-termini of the IRS proteins that activate signaling pathways selectively downstream of either IRS-1 or IRS-2. For example, Rho-kinase (ROCK), which regulates cell adhesion and motility, is reported to be activated downstream of IRS-2 91. A recent proteomic analysis of potential IRS-1 and IRS-2 interacting partners provides further evidence that unique effectors can interact with each adaptor protein 33. Distinct intracellular compartmentalization of IRS-1 and IRS-2 or differential sensitivities of IRS-1 and IRS-2 to negative feedback regulation would also impact the signaling outcomes of these adaptor proteins 4992. Additionally, acetylation positively regulates tyrosine phosphorylation of IRS-1 and negatively regulates tyrosine phosphoryaltion of IRS-2, which demonstrates that the function of these adaptor proteins can be differentially regulated by post-translational modifications 939495.

An alternative mechanism for the differential involvement of IRS-1 and IRS-2 in cancer that would allow for the activation of a common signaling pathway by these adaptor proteins was revealed during the analysis of Irs1-/- mammary tumors. Akt and mTor activation were enhanced significantly in Irs1-/- mammary tumors when compared with the level of activation in wildtype tumors 79. Although signaling through IRS-1 can activate these pathways in response to insulin or IGF-1 in many other model systems, when Irs-2 expression and function were compared between Irs1-/- and WT tumors, Irs-2 activity was significantly higher in the absence of Irs-1, a finding that is mimicked by transient suppression of Irs-1 by siRNA in vitro 79. A corresponding upregulation of Irs-1 expression and function is not observed in Irs-2-/- tumors, or when Irs-2 expression is suppressed by siRNA (S. Pankratz, personal observation). Importantly, suppression of Irs-2 expression in Irs1-/- tumor cells restores mTor activation to wildtype levels, confirming the contribution of Irs-2 to the increased mTor activity 79. These in vitro findings support the hypothesis that Irs-2 compensates for the loss of Irs-1, and in doing so, enhances the activation of signaling pathways that promote tumor metastasis. A similar compensatory upregulation of Irs-2 expression in Irs-1-/- mouse embryo fibroblasts has been hypothesized to explain the dominant role that IRS-2 plays in metabolic regulation 96.

IRS-4

IRS-4 expression increases in response to partial hepatectomy, a liver regeneration model, and expression is higher in hepatocellular tumors when compared with normal liver tissue 3997. In HepG2 hepatocellular carcinoma cells, suppression of IRS-4 expression by siRNA decreases IGF-1-dependent proliferation, which correlates with reduced Erk and p70S6-kinase activation 98. Irs-4 has also been implicated in the insulin-dependent proliferation of a murine T-cell lymphoma cell line and it is overexpressed in a pediatric T-cell acute lymphoblastic leukaemia (T-ALL) that harbors a breakpoint fusion between the T-cell receptor beta locus and the IRS-4 gene 99100. These studies suggest that IRS-4 functions more similarly to IRS-1 than IRS-2 in cancer in that it is associated with tumor proliferation.

Regulation of IRS expression

The evidence supporting the contribution of the IRS proteins to both tumor initiation and progression highlights the importance of understanding how the expression of these adaptor proteins is regulated. The differential expression patterns of the IRS proteins in both normal tissues and tumors support that their expression is likely regulated by unique mechanisms. Both the IRS-1 and IRS-2 genes are hormone-responsive, with IRS-1 regulated by the ER and IRS-2 regulated by the progesterone receptor (PR). Estrogen upregulates IRS-1 in ER+ breast carcinoma cells and IRS-1 expression decreases in response to the ER antagonists tamoxifen and ICI 182,780 101102103104. This inhibition of IRS-1 expression may contribute to the suppression of breast cancer by these antiestrogens 101102. Progestin stimulation prior to IGF-1 treatment of PR+ breast carcinoma cells upregulates IRS-2 expression levels and tyrosine phosphorylation, thereby enhancing downstream IRS-2-dependent signals 105106107.

Non-hormone-dependent pathways also regulate the IRS genes. E-box elements in the IRS-1 promoter and proteins that bind to these elements positively regulate IRS-1 expression in HepG2 hepatocellular carcinoma cells 108. E-boxes are often found in promoters of genes involved in metabolism and are consensus cis-elements for members of the basic helix-loop-helix family of transcription factors. IRS-2 is positively regulated by the cAMP-mediated activation of CREB, a pathway that is essential for the expression of this adaptor protein in pancreatic β-cells 109. Members of the Forkhead transcription family, including FOXO1 and FOXO3a, can also positively regulate IRS-2 expression 110. Several growth factor/hormone signaling pathways that are associated with cancer including fibroblast growth factor (FGF), epidermal growth factor (EGF) and insulin can modulate IRS-1 and IRS-2 expression levels 86111112113. The EGF-induced upregulation of IRS-2 expression occurs through a JNK/c-Jun/AP-1 pathway 86. IRS-1 expression is negatively regulated by all-trans retinoic acid (ATRA), which arrests the growth of ovarian carcinoma cells in G0–G1 44.

Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator-3 (SRC-3), regulates both IRS-1 and IRS-2 expression 114115. AIB1 is an oncogene that is often overexpressed in human tumors and it promotes the growth of hormone-insensitive tumor cells through its action as a coactivator of nuclear receptors 116. AIB1 directly regulates IRS-1 transcription by cooperating with the AP-1 transcription factor 115. The importance of this IRS-1 regulatory pathway is demonstrated by the fact that deletion of AIB1 has a protective effect on mouse mammary glands against carcinogen-induced tumorigenesis, which can be explained in part by decreased IRS-1 expression and decreased Akt signaling 117. The breast cancer-associated gene-1 (BRCA1) is a tumor suppressor that is mutated or deleted in 10% of hereditary breast cancers 118. BRCA1 interacts directly with the IRS-1 promoter and inhibits transcription of the IRS-1 gene through epigenetic modification of histone H3 and H4 119. Deletion of BRCA1 in mice leads to increased expression of some members of the IGF-1 signaling pathway, including IRS-1 119. The association of IRS-1 expression with BRCA1 provides additional support for the involvement of this IRS family member in tumor initiation.

At the post-transcriptional level, two microRNAs, miR-126 and miR-145, have been identified that target and suppress IRS-1 protein expression 120121122. Both miR-126 and miR-145 inhibit cell growth and their expression is frequently decreased in many cancer types 120121123124. Taken together, these findings are in keeping with a growth-promoting role for IRS-1 in tumors. miR-145 has also been implicated in positively regulating embryonic stem cell differentiation 125. Interestingly, IRS-1 promotes stem cell self-renewal and its expression decreases during embryonic stem cell differentiation when miR-145 expression increases 126. To date, miRNAs that target other IRS family members have not been identified.

Feedback regulation of IRS function and expression

The expression and function of the IRS proteins can be regulated post-translationally. Negative feedback regulation of the IRS proteins by serine phosphorylation was first demonstrated in insulin-dependent signaling, and this feedback pathway is essential for regulating insulin sensitivity and glucose homeostasis by limiting the magnitude and duration of the insulin signaling response 49127128129. Serine phosphorylation of the IRS proteins interferes with their function by targeting these adaptor proteins for inactivation and/or proteasomal degradation (Figure 3) 49. Phosphorylation on specific residues, such as serines 302 and 307, disrupts IRS-1 function by inhibiting interactions between the IRS-1 PTB domain and upstream receptors 130131. As a result, IRS-1 is not phosphorylated on tyrosine residues and cannot organize downstream signaling complexes 130132. IRS-1 and IRS-2 have also been shown to interact with 14-3-3 proteins through phosphoserine residues within the PTB domain 133. Binding of 14-3-3 proteins to the PTB domain may physically prevent the IRS proteins from interacting with upstream receptors, which prevents IRS-mediated signaling.

<p>Figure 3</p>

Negative feedback regulation of IRS-1

Negative feedback regulation of IRS-1. Serine residues that are phosphorylated in IRS-1 and the kinases that target these sites are indicated. Kinases shown in purple mediate signaling events that impede IRS-1 localization to the membrane or upstream receptors by disrupting PH and/or PTB domain function. Kinases shown in orange mediate signaling events that interfere with PI3K recruitment and activation. Kinases shown in pink mediate signaling events that result in phosphorylation of S789. Kinases that initiate signaling events that result in phosphorylation of S1223 and interfere with SHP-2 binding are unknown (yellow). Exogenous stimuli that have been implicated in cancer and that can activate kinases to regulate IRS-1 serine phosphorylation are indicated.

Serine phosphorylation of the IRS proteins can also directly interfere with interactions with downstream effectors and selectively prevent their activation 131134. For example, phosphorylation of serine residues within the PI3K-binding region can inhibit interactions between the IRS proteins and p85, the regulatory subunit of PI3K 135. In metastatic mouse mammary tumors, Irs-1 is phosphorylated on serine residues in the PI3K binding region and the association with p85 is decreased when compared with non-metastatic tumors 79. Phosphorylation of serine-1223 in IRS-1 interferes with recruitment of the tyrosine phosphatase SHP-2 and, as a result, IRS-1 tyrosine phosphorylation is enhanced 136. As mentioned previously, the distinct functions of IRS-1 and IRS-2 in tumor progression may reflect a differential sensitivity of IRS-1 and IRS-2 to the effects of negative feedback regulation, which could alter the longevity and intensity of signals initiated through each adaptor protein 112137138.

In addition to disrupting protein-protein interactions, serine phosphorylation of IRS-1 and IRS-2 can target these adaptor proteins for ubiquitination and degradation via the 26S proteasome 139140141. This downregulation is mediated by an mTOR-dependent negative feedback loop that also involves p70S6-kinase 134142143144145. In an extreme example of this negative feedback, tumors with constitutive activation of mTOR, such as those with mutations in the TSC-1 or TSC-2 genes, are benign and rarely progress to a more malignant state because both IRS-1 and IRS-2 are degraded and cannot sufficiently activate survival signals 143144146. mTOR can also regulate proteasome-dependent degradation of the IRS proteins by stimulating the endoplasmic reticulum stress (ER-stress) response. Loss of TSC function and subsequent mTORC1 activation lead to ER-stress and activation of the unfolded protein response (UPR) 147. Inhibition of ER-stress in TSC-1-/- or TSC-2-/- cells that have decreased expression of IRS-1 and IRS-2 results in increased IRS protein stability and insulin-induced tyrosine-phosphorylation, which leads to enhanced Akt activation. Likewise, induction of ER-stress dramatically increases IRS-1 ubiquitination-dependent proteasomal degradation 147.

A significant amount of research has focused on understanding the contribution of IRS serine phosphorylation to insulin resistance and diabetes and the information gained from these studies can be applied to cancer (reviewed in 49) (Figure 3). For example, the inflammatory cytokine tumor necrosis factor-α (TNF-α) inactivates IRS-1 through a JNK-mediated phosphorylation of S307 (S312 in human IRS-1), which results in insulin resistance 127131. Inflammatory cells in the tumor microenvironment secrete TNF-α and other cytokines that positively contribute to tumor progression. Therefore, serine phosphorylation of the IRS proteins may be a mechanism by which the stromal microenvironment influences tumor behavior 148. Additional exogenous factors that can regulate IRS serine phosphorylation levels and that are associated with cancer progression include elevated free fatty acids, obesity and oxidative stress 149150151152. Potential intrinsic mechanisms to phosphorylate and regulate IRS function include many kinases that are activated by oncogenic signaling, including mTor, Akt, multiple PKC family members, Erk1/2, S6-kinase, IKKβ, AMPK and SIK, as well as the aforementioned JNK 49153. Additional studies are warranted to determine the potential of these IRS feedback pathways as therapeutic targets for cancer treatment.

IRS signaling functions can be influenced by additional post-translational modifications including O-linked glycosylation and, as mentioned previously, acetylation. Increased activation of the hexosamine pathway (HBP) can induce O-glycosylation of IRS-1 and IRS-2, which decreases IRS tyrosine-phosphorylation and prevents activation of the PI3K signaling pathway 154155. Acetylation of IRS-1 and IRS-2 decreases or increases, respectively, their level of tyrosine phosphorylation and downstream signaling. IRS-1 deacetylation is mediated by HDAC2 and IRS-2 deacetylation is mediated by SirT1 939495. However, neither of these IRS posttranslational modifications have been investigated in the context of cancer and it is not known if they contribute to the regulation of IRS-dependent signaling in tumor cells.

Involvement of the IRS proteins in transformation

The transforming potential of the IRS proteins has been demonstrated in several different model systems, with most of the evidence coming from studies on IRS-1. The earliest indication that IRS-1 had oncogenic potential came from studies on IGF-1R null 3T3 fibroblasts (R- cells), which are resistant to transformation by a number of oncogenes, including SV40 T-antigen 156157. Overexpression of IRS-1 in these R- cells cooperates with both SV40 T-antigen and Src to promote transformation, whereas in wildtype 3T3 cells, suppression of IRS-1 expression inhibits SV40 T-antigen-mediated transformation 158159. Subsequent studies have demonstrated that overexpression of IRS-1 in 3T3 fibroblasts, independent of SV40 T-antigen, promotes growth in soft agar and tumorigenicity in nude mice 160. IRS-1 also cooperates with V-HA-Ras to transform 32D murine hematopoietic cells 161. IRS-1 tyrosine phosphorylation and activation of MAPK, SHP-2 and PI3K signaling pathways have been implicated in the mechanism by which this adaptor protein promotes transformation 161162163. Overexpression of both IRS-1 and IRS-2 in immortalized mammary epithelial cells disrupts normal luminal differentiation and polarization and promotes dysregulated growth 76. Moreover, as mentioned previously, transgenic overexpression of IRS-1 or IRS-2 in the mammary gland results in hyperplasia, tumor development and metastasis. Tumors that arise in response to overexpression of IRS-1 and IRS-2 have increased β-catenin signaling as evidenced by the upregulation of downstream target genes cyclin D1 and c-Myc 76. These in vivo studies confirm the oncogenic potential of both of these adaptor proteins.

IRS-1 has been implicated in the development of medulloblastomas through an interaction with the T-antigen of human polyomavirus JC (JCV T-antigen). Medulloblastoma cell lines and biopsies express high levels of the IGF-1R and IRS-1, the latter of which co-localizes with the JCV T-antigen in the nucleus 164. Disruption of the interaction between IRS-1 and the JCV T-antigen using a dominant negative mutant of IRS-1 inhibits the anchorage-independent growth and survival of JCV T-antigen transformed medulloblastoma cells 164. More recently IRS-1 and IRS-4 have been shown to play a role in transformation by adenovirus 5 early region 1A (Ad5E1A) by binding to the Ad5E1A protein 165. Ad5E1A association with the IRS proteins results in increased IRS tyrosine phosphorylation and subsequent constitutive activation of the PI3K/Akt signaling pathway.

Nuclear functions for the IRS proteins

The majority of studies that have investigated IRS function in cancer have focused on their role as cytoplasmic adaptor proteins. However, there is accumulating evidence that the IRS proteins may also have important functions in the nucleus. As mentioned above when discussing the transforming potential of the IRS proteins, IRS-1 co-localizes with the SV40 and JCV T-antigens in the nuclei of transformed cells 166167. Independently of any oncogenic stimulus, IGF-1 stimulation can also promote the nuclear localization of IRS-1 168. Recently, a positive correlation between IRS-1 nuclear expression and a more well-differentiated, non-metastatic phenotype for ductal breast cancer was reported 46. These findings provide additional evidence that the IRS proteins may have distinct functions that are dependent upon their localization within the cell and that the activity of these adaptor proteins can be regulated by recruitment to or exclusion from a specific intracellular compartment.

With regard to function in the nucleus, IRS-1 can be detected on promoter sequences of several genes, including c-myc, Cyclin D1 and ER target genes 169170. Studies in breast carcinoma cells reveal interactions between IRS-1 and the transcription factors β-catenin, ER-α and the androgen receptor (AR) 76169171172. Interactions of IRS-1 with β-catenin and AR positively regulate transcription, whereas IRS-1 antagonizes ER-dependent expression of genes that contain estrogen response elements (EREs) 169. Although IRS-1 is capable of directing nuclear localization of β-catenin, ER-α is responsible for the nuclear translocation of IRS-1 in response to estrogen treatment 169. IRS-1 also interacts with upstream binding factor-1 (UBF1) and regulates RNA polymerase activity to increase ribosomal RNA synthesis 173.

A role for IRS-1 in DNA repair has also been reported. In normal cells, IRS-1 binds to Rad51, a key enzyme in homologous recombination-directed DNA repair (HRR), and regulates its recruitment into the nucleus in response to agents that cause double strand breaks 174. Phosphorylation of IRS-1 on tyrosine residues disrupts its interaction with Rad-51 and allows Rad51 to translocate into the nucleus to initiate DNA repair. In the absence of IGF-1 signaling, the IRS-1/Rad51 interaction is maintained and repair is impeded 174. In medulloblastomas, IRS-1 translocates to the nucleus with ERβ or the JCV T-antigen, where it interacts with Rad51 and prevents HRR, rendering these tumors more sensitive to genotoxic agents such as cisplatin 175176.

Conclusion

The IRS proteins have been implicated in contributing to all stages of cancer, from initiating events to metastatic progression. However, there is still much to be learned about the mechanisms by which each of the IRS proteins differentially contribute to tumor cell function and the manner in which their expression and function are regulated. Understanding how the tumor microenvironment and other oncogenic signaling pathways impinge upon the IRS proteins to influence their signaling functions is essential for the future development of these adaptor proteins as either predictive markers for drug responsiveness or as therapeutic targets themselves. Given that IRS-1 and IRS-2 mediate distinct cellular responses to IGF-1stimulation, their relative expression levels and functional status are likely to impact the response of tumors to therapies that target the IGF-1 signaling axis. Assays that can determine not only the expression of the IRS family members but also their functional status will need to be developed to identify patients that are likely to be responsive to this targeted therapy and what outcomes should be anticipated.

The contribution of the IRS proteins to drug resistance is another important area for future investigation. The expression and function of the IRS proteins are tightly regulated by negative feedback loops, many of which are disrupted by drugs that target oncogenic signaling pathways. For example, prolonged inhibition of EGFR or MAPK signaling prevents the MAPK-mediated degradation of IRS-1, which increases IGF-1R signaling and resistance to EGFR-inhibition therapy 177178. Likewise, resistance to rapamycin treatment can occur through the upregulation of IRS-1-mediated PI3K signaling that occurs due to the disruption of S6-kinase-mediated degradation of the IRS proteins 138143. Taken together, these studies reveal the importance of negative feedback regulation of the IRS proteins and underscore the importance of assessing IRS expression and function when designing new therapies that will disrupt these feedback mechanisms.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All of the authors contributed to the writing of this manuscript. All of the authors have read and approved the final manuscript.

Acknowledgements

This work was supported by NIH grant CA090583 and Susan G. Komen for the Cure grant BCTR0706837 (LMS), American Cancer Society New England Division-Virginia Cochary Award for Excellence in Breast Cancer Research Postdoctoral Fellowship PF-07-104-01-CSM (SLP) and Department of Defense Breast Cancer Predoctoral Fellowship BC073053 (KM).

 <p>I nsulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells</p> White MF Maron R Kahn CR Nature 1985 318 6042 183 186 10.1038/318183a0 2414672 <p>4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice</p> Patti ME Sun XJ Bruening JC Araki E Lipes MA White MF Kahn CR J Biol Chem 1995 270 42 24670 24673 10.1074/jbc.270.42.24670 7559579 <p>IRS proteins and the common path to diabetes</p> White MF Am J Physiol Endocrinol Metab 2002 283 3 E413 422 12169433 <p>A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family</p> Lavan BE Fantin VR Chang ET Lane WS Keller SR Lienhard GE J Biol Chem 1997 272 34 21403 21407 10.1074/jbc.272.34.21403 9261155 <p>The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family</p> Lavan BE Lane WS Lienhard GE J Biol Chem 1997 272 17 11439 11443 10.1074/jbc.272.17.11439 9111055 <p>Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans</p> Bjornholm M He AR Attersand A Lake S Liu SC Lienhard GE Taylor S Arner P Zierath JR Diabetologia 2002 45 12 1697 1702 10.1007/s00125-002-0945-z 12488959 <p>Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation</p> Grimm J Sachs M Britsch S Di Cesare S Schwarz-Romond T Alitalo K Birchmeier W J Cell Biol 2001 154 2 345 354 2150770 11470823 10.1083/jcb.200102032 <p>DOK4 and DOK5: new Dok-related genes expressed in human T cells</p> Favre C Gerard A Clauzier E Pontarotti P Olive D Nunes JA Genes Immun 2003 4 1 40 45 10.1038/sj.gene.6363891 12595900 <p>Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5</p> Cai D Dhe-Paganon S Melendez PA Lee J Shoelson SE J Biol Chem 2003 278 28 25323 25330 10.1074/jbc.M212430200 12730241 <p>Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene</p> Araki E Lipes MA Patti ME Bruning JC Haag B 3rd Johnson RS Kahn CR Nature 1994 372 6502 186 190 10.1038/372186a0 7526222 <p>Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1</p> Tamemoto H Kadowaki T Tobe K Yagi T Sakura H Hayakawa T Terauchi Y Ueki K Kaburagi Y Satoh S Nature 1994 372 6502 182 186 10.1038/372182a0 7969452 <p>Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1–4</p> Bohni R Riesgo-Escovar J Oldham S Brogiolo W Stocker H Andruss BF Beckingham K Hafen E Cell 1999 97 7 865 875 10.1016/S0092-8674(00)80799-0 10399915 <p>Disruption of IRS-2 causes type 2 diabetes in mice</p> Withers DJ Gutierrez JS Towery H Burks DJ Ren JM Previs S Zhang Y Bernal D Pons S Shulman GI Bonner-Weir S White MF Nature 1998 391 6670 900 904 10.1038/36116 9495343 <p>Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation</p> Schubert M Brazil DP Burks DJ Kushner JA Ye J Flint CL Farhang-Fallah J Dikkes P Warot XM Rio C Corfas G White MF J Neurosci 2003 23 18 7084 7092 12904469 <p>Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling</p> Withers DJ Burks DJ Towery HH Altamuro SL Flint CL White MF Nat Genet 1999 23 1 32 40 10.1038/12631 10471495 <p>IRS-2 pathways integrate female reproduction and energy homeostasis</p> Burks DJ de Mora JF Schubert M Withers DJ Myers MG Towery HH Altamuro SL Flint CL White MF Nature 2000 407 6802 377 382 10.1038/35030105 11014193 <p>Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis</p> Fantin VR Wang Q Lienhard GE Keller SR Am J Physiol Endocrinol Metab 2000 278 1 E127 133 10644546 <p>Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein</p> Sun XJ Rothenberg P Kahn CR Backer JM Araki E Wilden PA Cahill DA Goldstein BJ White MF Nature 1991 352 6330 73 77 10.1038/352073a0 1648180 <p>Tyrosine phosphorylation of insulin receptor substrate-1 in vivo depends upon the presence of its pleckstrin homology region</p> Voliovitch H Schindler DG Hadari YR Taylor SI Accili D Zick Y J Biol Chem 1995 270 30 18083 18087 10.1074/jbc.270.30.18083 7629118 <p>The pleckstrin homology domain is the principal link between the insulin receptor and IRS-1</p> Yenush L Makati KJ Smith-Hall J Ishibashi O Myers MG Jr White MF J Biol Chem 1996 271 39 24300 24306 10.1074/jbc.271.39.24300 8798677 <p>Heterologous pleckstrin homology domains do not couple IRS-1 to the insulin receptor</p> Burks DJ Pons S Towery H Smith-Hall J Myers MG Jr Yenush L White MF J Biol Chem 1997 272 44 27716 27721 10.1074/jbc.272.44.27716 9346913 <p>Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591–786</p> Sawka-Verhelle D Tartare-Deckert S White MF Van Obberghen E J Biol Chem 1996 271 11 5980 5983 10.1074/jbc.271.11.5980 8626379 <p>In vitro binding and phosphorylation of insulin receptor substrate 1 by the insulin receptor. Role of interactions mediated by the phosphotyrosine-binding domain and the pleckstrin-homology domain</p> Backer JM Wjasow C Zhang Y Eur J Biochem 1997 245 1 91 96 10.1111/j.1432-1033.1997.t01-1-00091.x 9128728 <p>Tyr624 and Tyr628 in insulin receptor substrate-2 mediate its association with the insulin receptor</p> Sawka-Verhelle D Baron V Mothe I Filloux C White MF Van Obberghen E J Biol Chem 1997 272 26 16414 16420 10.1074/jbc.272.26.16414 9195949 <p>Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1</p> Sun XJ Crimmins DL Myers MG Jr Miralpeix M White MF Mol Cell Biol 1993 13 12 7418 7428 364813 7504175 <p>Role of IRS-2 in insulin and cytokine signalling</p> Sun XJ Wang LM Zhang Y Yenush L Myers MG Jr Glasheen E Lane WS Pierce JH White MF Nature 1995 377 6545 173 177 10.1038/377173a0 7675087 <p>Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells</p> Lee CH Li W Nishimura R Zhou M Batzer AG Myers MG Jr White MF Schlessinger J Skolnik EY Proc Natl Acad Sci USA 1993 90 24 11713 11717 48054 8265614 10.1073/pnas.90.24.11713 <p>Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation</p> Myers MG Jr Grammer TC Wang LM Sun XJ Pierce JH Blenis J White MF J Biol Chem 1994 269 46 28783 28789 7961833 <p>Role of IRS-1-GRB-2 complexes in insulin signaling</p> Myers MG Jr Wang LM Sun XJ Zhang Y Yenush L Schlessinger J Pierce JH White MF Mol Cell Biol 1994 14 6 3577 3587 358725 8196603 <p>The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling</p> Beitner-Johnson D Blakesley VA Shen-Orr Z Jimenez M Stannard B Wang LM Pierce J LeRoith D J Biol Chem 1996 271 16 9287 9290 10.1074/jbc.271.16.9287 8621590 <p>The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling</p> Myers MG Jr Mendez R Shi P Pierce JH Rhoads R White MF J Biol Chem 1998 273 41 26908 26914 10.1074/jbc.273.41.26908 9756938 <p>The insulin-like growth factor I receptor-induced interaction of insulin receptor substrate-4 and Crk-II</p> Karas M Koval AP Zick Y LeRoith D Endocrinology 2001 142 5 1835 1840 10.1210/en.142.5.1835 11316748 <p>The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2</p> Hanke S Mann M Mol Cell Proteomics 2009 8 3 519 534 19001411 <p>Increased expression of insulin receptor substrate-1 in human pancreatic cancer</p> Bergmann U Funatomi H Kornmann M Beger HG Korc M Biochem Biophys Res Commun 1996 220 3 886 890 10.1006/bbrc.1996.0500 8607861 <p>Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer</p> Kornmann M Maruyama H Bergmann U Tangvoranuntakul P Beger HG White MF Korc M Cancer Res 1998 58 19 4250 4254 9766646 <p>Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease</p> Hellawell GO Turner GD Davies DR Poulsom R Brewster SF Macaulay VM Cancer Res 2002 62 10 2942 2950 12019176 <p>Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes</p> Hoang CD Zhang X Scott PD Guillaume TJ Maddaus MA Yee D Kratzke RA Cancer Res 2004 64 20 7479 7485 10.1158/0008-5472.CAN-04-1898 15492273 <p>Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma</p> Boissan M Beurel E Wendum D Rey C Lecluse Y Housset C Lacombe ML Desbois-Mouthon C Am J Pathol 2005 167 3 869 877 1698721 16127164 <p>Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms</p> Cantarini MC de la Monte SM Pang M Tong M D'Errico A Trevisani F Wands JR Hepatology 2006 44 2 446 457 10.1002/hep.21272 16871543 <p>Irs2 inactivation suppresses tumor progression in Pten +/- mice</p> Szabolcs M Keniry M Simpson L Reid LJ Koujak S Schiff SC Davidian G Licata S Gruvberger-Saal S Murty VV Nandula S Efstratiadis A Kushner JA White MF Parsons R Am J Pathol 2009 174 1 276 286 10.2353/ajpath.2009.080086 19095950 2631340 <p>Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival</p> Rocha RL Hilsenbeck SG Jackson JG VanDenBerg CL Weng C Lee AV Yee D Clin Cancer Res 1997 3 1 103 109 9815544 <p>Insulin-like growth factor I receptor activity in human medulloblastomas</p> Del Valle L Enam S Lassak A Wang JY Croul S Khalili K Reiss K Clin Cancer Res 2002 8 6 1822 1830 12060623 <p>Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases</p> Koda M Sulkowska M Kanczuga-Koda L Sulkowski S J Clin Pathol 2005 58 6 645 649 1770676 15917419 10.1136/jcp.2004.022590 <p>Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid</p> Ravikumar S Perez-Liz G Del Vale L Soprano DR Soprano KJ Cancer Res 2007 67 19 9266 9275 10.1158/0008-5472.CAN-07-2088 17909034 <p>Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer</p> Schnarr B Strunz K Ohsam J Benner A Wacker J Mayer D Int J Cancer 2000 89 6 506 513 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F 11102895 <p>Expression of nuclear insulin receptor substrate 1 (IRS-1) in breast cancer</p> Sisci D Morelli C Garofalo C Romeo F Morabito L Casaburi F Middea E Cascio S Brunelli E Ando S Surmacz E J Clin Pathol 2006 60 633 641 10.1136/jcp.2006.039107 16882697 <p>Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer</p> Han CH Cho JY Moon JT Kim HJ Kim SK Shin DH Chang J Ahn CM Kim SK Chang YS Oncol Rep 2006 16 6 1205 1210 17089038 <p>DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma</p> Al-Sarraf N Reiff JN Hinrichsen J Mahmood S Teh BT McGovern E De Meyts P O'Byrne KJ Gray SG Int J Cancer 2007 121 5 992 998 10.1002/ijc.22776 17443497 <p>Positive and negative regulation of insulin signaling through IRS-1 phosphorylation</p> Gual P Le Marchand-Brustel Y Tanti JF Biochimie 2005 87 1 99 109 10.1016/j.biochi.2004.10.019 15733744 <p>The IGF system and breast cancer</p> Sachdev D Yee D Endocr Relat Cancer 2001 8 3 197 209 10.1677/erc.0.0080197 11566611 <p>The insulin-like growth factor system and cancer</p> LeRoith D Roberts CT Jr Cancer Lett 2003 195 2 127 137 12767520 <p>Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer</p> Resnik JL Reichart DB Huey K Webster NJ Seely BL Cancer Res 1998 58 6 1159 1164 9515800 <p>Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis</p> Renehan AG Zwahlen M Minder C O'Dwyer ST Shalet SM Egger M Lancet 2004 363 9418 1346 1353 10.1016/S0140-6736(04)16044-3 15110491 <p>Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase</p> Yamauchi T Kaburagi Y Ueki K Tsuji Y Stark GR Kerr IM Tsushima T Akanuma Y Komuro I Tobe K Yazaki Y Kadowaki T J Biol Chem 1998 273 25 15719 15726 10.1074/jbc.273.25.15719 9624169 <p>Insulin receptor substrate-1 enhances growth hormone-induced proliferation</p> Liang L Zhou T Jiang J Pierce JH Gustafson TA Frank SJ Endocrinology 1999 140 5 1972 1983 10.1210/en.140.5.1972 10218944 <p>The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway</p> Senthil D Ghosh Choudhury G Bhandari BK Kasinath BS Biochem J 2002 368 Pt 1 49 56 1222964 12153400 10.1042/BJ20020137 <p>Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib</p> Morgillo F Woo JK Kim ES Hong WK Lee HY Cancer Res 2006 66 20 10100 10111 10.1158/0008-5472.CAN-06-1684 17047074 <p>Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance</p> Knowlden JM Jones HE Barrow D Gee JM Nicholson RI Hutcheson IR Breast Cancer Res Treat 2008 111 1 79 91 10.1007/s10549-007-9763-9 17902048 <p>Association of insulin receptor substrate-1 with integrins</p> Vuori K Ruoslahti E Science 1994 266 5190 1576 1578 10.1126/science.7527156 7527156 <p>Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion</p> Shaw LM Mol Cell Biol 2001 21 15 5082 5093 87234 11438664 10.1128/MCB.21.15.5082-5093.2001 <p>Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins</p> Goel HL Fornaro M Moro L Teider N Rhim JS King M Languino LR J Cell Biol 2004 166 3 407 418 2172270 15289498 10.1083/jcb.200403003 <p>Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)</p> Fujimoto J Shiota M Iwahara T Seki N Satoh H Mori S Yamamoto T Proc Natl Acad Sci USA 1996 93 9 4181 4186 39508 8633037 10.1073/pnas.93.9.4181 <p>Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells</p> Miyagi E Braga-Basaria M Hardy E Vasko V Burman KD Jhiang S Saji M Ringel MD Mol Carcinog 2004 41 2 98 107 10.1002/mc.20042 15378648 <p>ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages</p> Lannon CL Sorensen PH Semin Cancer Biol 2005 15 3 215 223 10.1016/j.semcancer.2005.01.003 15826836 <p>Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin</p> Stoica GE Kuo A Aigner A Sunitha I Souttou B Malerczyk C Caughey DJ Wen D Karavanov A Riegel AT Wellstein A J Biol Chem 2001 276 20 16772 16779 10.1074/jbc.M010660200 11278720 <p>Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells</p> Nolan MK Jankowska L Prisco M Xu S Guvakova MA Surmacz E Int J Cancer 1997 72 5 828 834 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3 9311601 <p>Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells</p> Jackson JG White MF Yee D J Biol Chem 1998 273 16 9994 10003 10.1074/jbc.273.16.9994 9545345 <p>Insulin receptor substrate 1 antisense expression in an hepatoma cell line reduces cell proliferation and induces overexpression of the Src homology 2 domain and collagen protein (SHC)</p> Taouis M Dupont J Gillet A Derouet M Simon J Mol Cell Endocrinol 1998 137 2 177 186 10.1016/S0303-7207(97)00245-1 9605520 <p>Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas</p> Wang JY Del Valle L Gordon J Rubini M Romano G Croul S Peruzzi F Khalili K Reiss K Oncogene 2001 20 29 3857 3868 10.1038/sj.onc.1204532 11439349 <p>Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells</p> Byron SA Horwitz KB Richer JK Lange CA Zhang X Yee D Br J Cancer 2006 95 9 1220 1228 10.1038/sj.bjc.6603354 17043687 <p>A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype</p> Tanaka S Wands JR J Clin Invest 1996 98 9 2100 2108 507655 8903330 10.1172/JCI119016 <p>PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model</p> Weng LP Smith WM Brown JL Eng C Hum Mol Genet 2001 10 6 605 616 10.1093/hmg/10.6.605 11230180 <p>Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis</p> Tanaka S Wands JR Cancer Res 1996 56 15 3391 3394 8758899 <p>RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells</p> Cesarone G Garofalo C Abrams MT Igoucheva O Alexeev V Yoon K Surmacz E Wickstrom E J Cell Biochem 2006 98 2 440 450 10.1002/jcb.20817 16440325 <p>Involvement of insulin receptor substrate 2 in mammary tumor metastasis</p> Nagle JA Ma Z Byrne MA White MF Shaw LM Mol Cell Biol 2004 24 22 9726 9735 525494 15509777 10.1128/MCB.24.22.9726-9735.2004 <p>Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2</p> Dearth RK Cui X Kim HJ Kuiatse I Lawrence NA Zhang X Divisova J Britton OL Mohsin S Allred DC Hadsell DL Lee AV Mol Cell Biol 2006 26 24 9302 9314 1698542 17030631 10.1128/MCB.00260-06 <p>Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes</p> Tanaka S Mohr L Schmidt EV Sugimachi K Wands JR Hepatology 1997 26 3 598 604 10.1002/hep.510260310 9303488 <p>Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptor</p> Wiedmann M Tamaki S Silberman R de la Monte SM Cousens L Wands JR J Hepatol 2003 38 6 803 810 10.1016/S0168-8278(03)00117-X 12763374 <p>Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis</p> Ma Z Gibson SL Byrne MA Zhang J White MF Shaw LM Mol Cell Biol 2006 26 24 9338 9351 1698550 17030605 10.1128/MCB.01032-06 <p>Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis</p> Gibson SL Ma Z Shaw LM Cell Cycle 2007 6 6 631 637 17361103 <p>Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9</p> Ramocki NM Wilkins HR Magness ST Simmons JG Scull BP Lee GH McNaughton KK Lund PK Endocrinology 2008 149 1 261 267 2194604 17916629 10.1210/en.2007-0869 <p>A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer</p> Dunn SE Ehrlich M Sharp NJ Reiss K Solomon G Hawkins R Baserga R Barrett JC Cancer Res 1998 58 15 3353 3361 9699666 <p>A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells</p> Sachdev D Hartell JS Lee AV Zhang X Yee D J Biol Chem 2004 279 6 5017 5024 10.1074/jbc.M305403200 14615489 <p>Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines</p> Jackson JG Zhang X Yoneda T Yee D Oncogene 2001 20 50 7318 7325 10.1038/sj.onc.1204920 11704861 <p>Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression</p> Zhang X Kamaraju S Hakuno F Kabuta T Takahashi S Sachdev D Yee D Breast Cancer Res Treat 2004 83 2 161 170 10.1023/B:BREA.0000010709.31256.c6 14997047 <p>Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration</p> Cui X Kim HJ Kuiatse I Kim H Brown PH Lee AV Cancer Res 2006 66 10 5304 5313 10.1158/0008-5472.CAN-05-2858 16707456 <p>Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells</p> Kim B Leventhal PS White MF Feldman EL Endocrinology 1998 139 12 4881 4889 10.1210/en.139.12.4881 9832424 <p>Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary tumor cells via glucose transporter 1</p> Pankratz SL Tan EY Fine Y Mercurio AM Shaw LM J Biol Chem 2009 284 4 2031 2037 10.1074/jbc.M804776200 19056742 <p>Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta</p> Kwon J Stephan S Mukhopadhyay A Muders MH Dutta SK Lau JS Mukhopadhyay D Cancer Res 2009 69 4 1350 1357 10.1158/0008-5472.CAN-08-1328 19190347 2705142 <p>IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85</p> Myers MG Jr Backer JM Sun XJ Shoelson S Hu P Schlessinger J Yoakim M Schaffhausen B White MF Proc Natl Acad Sci USA 1992 89 21 10350 10354 50336 1332046 10.1073/pnas.89.21.10350 <p>Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration</p> Zhang X Lin M van Golen KL Yoshioka K Itoh K Yee D Breast Cancer Res Treat 2005 93 2 159 168 10.1007/s10549-005-4626-8 16187236 <p>Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes</p> Fasshauer M Klein J Ueki K Kriauciunas KM Benito M White MF Kahn CR J Biol Chem 2000 275 33 25494 25501 10.1074/jbc.M004046200 10829031 <p>Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation</p> Kaiser C James SR BMC Biol 2004 2 23 529456 15522123 10.1186/1741-7007-2-23 <p>The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation</p> Zhang J J Biol Chem 2007 282 47 34356 34364 10.1074/jbc.M706644200 17901049 <p>SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons</p> Li Y Xu W McBurney MW Longo VD Cell Metab 2008 8 1 38 48 10.1016/j.cmet.2008.05.004 18590691 <p>The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling</p> Guo S Dunn SL White MF Mol Endocrinol 2006 20 12 3389 3399 10.1210/me.2006-0092 16916938 <p>Insulin receptor substrate-4 signaling in quiescent rat hepatocytes and in regenerating rat liver</p> Escribano O Fernandez-Moreno MD Zueco JA Menor C Fueyo J Ropero RM Diaz-Laviada I Roman ID Guijarro LG Hepatology 2003 37 6 1461 1469 10.1053/jhep.2003.50245 12774026 <p>Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2 proliferation</p> Cuevas EP Escribano O Chiloeches A Ramirez Rubio S Roman ID Fernandez-Moreno MD Guijarro LG J Hepatol 2007 46 6 1089 1098 10.1016/j.jhep.2007.01.031 17408801 <p>IRS-4 mediated mitogenic signalling by insulin and growth hormone in LB cells, a murine T-cell lymphoma devoid of IGF-I receptors</p> Urso B Ilondo MM Holst PA Christoffersen CT Ouwens M Giorgetti S Van Obberghen E Naor D Tornqvist H De Meyts P Cell Signal 2003 15 4 385 394 10.1016/S0898-6568(02)00113-4 12618213 <p>The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus</p> Karrman K Kjeldsen E Lassen C Isaksson M Davidsson J Andersson A Hasle H Fioretos T Johansson B Br J Haematol 2009 144 4 546 551 10.1111/j.1365-2141.2008.07453.x 19055661 <p>Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells</p> Guvakova MA Surmacz E Cancer Res 1997 57 13 2606 2610 9205064 <p>Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells</p> Salerno M Sisci D Mauro L Guvakova MA Ando S Surmacz E Int J Cancer 1999 81 2 299 304 10.1002/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.0.CO;2-8 10188734 <p>Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo</p> Lee AV Jackson JG Gooch JL Hilsenbeck SG Coronado-Heinsohn E Osborne CK Yee D Mol Endocrinol 1999 13 5 787 796 10.1210/me.13.5.787 10319328 <p>Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line [In Process Citation]</p> Molloy CA May FE Westley BR J Biol Chem 2000 275 17 12565 12571 10.1074/jbc.275.17.12565 10777546 <p>Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene</p> Vassen L Wegrzyn W Klein-Hitpass L Mol Endocrinol 1999 13 3 485 494 10.1210/me.13.3.485 10077005 <p>Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2</p> Cui X Lazard Z Zhang P Hopp TA Lee AV Oncogene 2003 22 44 6937 6941 10.1038/sj.onc.1206803 14534541 <p>Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2</p> Ibrahim YH Byron SA Cui X Lee AV Yee D Mol Cancer Res 2008 6 9 1491 1498 10.1158/1541-7786.MCR-07-2173 18819936 <p>Cell-specific regulation of IRS-1 gene expression: role of E box and C/EBP binding site in HepG2 cells and CHO cells</p> Matsuda K Araki E Yoshimura R Tsuruzoe K Furukawa N Kaneko K Motoshima H Yoshizato K Kishikawa H Shichiri M Diabetes 1997 46 3 354 362 10.2337/diabetes.46.3.354 9032089 <p>cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2</p> Jhala US Canettieri G Screaton RA Kulkarni RN Krajewski S Reed J Walker J Lin X White M Montminy M Genes Dev 2003 17 13 1575 1580 196130 12842910 10.1101/gad.1097103 <p>SREBPs suppress IRS-2-mediated insulin signalling in the liver</p> Ide T Shimano H Yahagi N Matsuzaka T Nakakuki M Yamamoto T Nakagawa Y Takahashi A Suzuki H Sone H Toyoshima H Fukamizu A Yamada N Nat Cell Biol 2004 6 4 351 357 10.1038/ncb1111 15048126 <p>Insulin inhibits transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes</p> Zhang J Ou J Bashmakov Y Horton JD Brown MS Goldstein JL Proc Natl Acad Sci USA 2001 98 7 3756 3761 31125 11259670 10.1073/pnas.071054598 <p>Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway</p> Hirashima Y Tsuruzoe K Kodama S Igata M Toyonaga T Ueki K Kahn CR Araki E J Endocrinol 2003 179 2 253 266 10.1677/joe.0.1790253 14596677 <p>Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway</p> Lassarre C Ricort JM Endocrinology 2003 144 11 4811 4819 10.1210/en.2002-0205 12960057 <p>AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice</p> Kuang SQ Liao L Zhang H Lee AV O'Malley BW Xu J Cancer Res 2004 64 5 1875 1885 10.1158/0008-5472.CAN-03-3745 14996752 <p>Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway</p> Yan J Yu CT Ozen M Ittmann M Tsai SY Tsai MJ Cancer Res 2006 66 22 11039 11046 10.1158/0008-5472.CAN-06-2442 17108143 <p>SRC-3/AIB1: transcriptional coactivator in oncogenesis</p> Yan J Tsai SY Tsai MJ Acta Pharmacol Sin 2006 27 4 387 394 10.1111/j.1745-7254.2006.00315.x 16539836 <p>Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis</p> Kuang SQ Liao L Wang S Medina D O'Malley BW Xu J Cancer Res 2005 65 17 7993 8002 16140972 <p>BRCA1 and BRCA2 and the genetics of breast and ovarian cancer</p> Welcsh PL King MC Hum Mol Genet 2001 10 7 705 713 10.1093/hmg/10.7.705 11257103 <p>Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members</p> Shukla V Coumoul X Cao L Wang RH Xiao C Xu X Ando S Yakar S Leroith D Deng C Cancer Res 2006 66 14 7151 7157 10.1158/0008-5472.CAN-05-4570 16849561 <p>Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells</p> Shi B Sepp-Lorenzino L Prisco M Linsley P deAngelis T Baserga R J Biol Chem 2007 282 45 32582 32590 10.1074/jbc.M702806200 17827156 <p>The cell growth suppressor, mir-126, targets IRS-1</p> Zhang J Du YY Lin YF Chen YT Yang L Wang HJ Ma D Biochem Biophys Res Commun 2008 377 1 136 140 10.1016/j.bbrc.2008.09.089 18834857 <p>Mechanism of growth inhibition by MicroRNA 145: The role of the IGF-I receptor signaling pathway</p> La Rocca G Badin M Shi B Xu SQ Deangelis T Sepp-Lorenzinoi L Baserga R J Cell Physiol 2009 220 2 485 491 10.1002/jcp.21796 19391107 <p>MicroRNA gene expression deregulation in human breast cancer</p> Iorio MV Ferracin M Liu CG Veronese A Spizzo R Sabbioni S Magri E Pedriali M Fabbri M Campiglio M Ménard S Palazzo JP Rosenberg A Musiani P Volinia S Nenci I Calin GA Querzoli P Negrini M Croce CM Cancer Res 2005 65 16 7065 7070 10.1158/0008-5472.CAN-05-1783 16103053 <p>Diagnostic and prognostic microRNAs in stage II colon cancer</p> Schepeler T Reinert JT Ostenfeld MS Christensen LL Silahtaroglu AN Dyrskjot L Wiuf C Sorensen FJ Kruhoffer M Laurberg S Kauppinen S Ørntoft TF Andersen CL Cancer Res 2008 68 15 6416 6424 10.1158/0008-5472.CAN-07-6110 18676867 <p>MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells</p> Xu N Papagiannakopoulos T Pan G Thomson JA Kosik KS Cell 2009 137 4 647 658 10.1016/j.cell.2009.02.038 19409607 <p>Insulin receptor substrate (IRS)-1 regulates murine embryonic stem (mES) cells self-renewal</p> Rubin R Arzumanyan A Soliera AR Ross B Peruzzi F Prisco M J Cell Physiol 2007 213 2 445 453 10.1002/jcp.21185 17620314 <p>The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)</p> Aguirre V Uchida T Yenush L Davis R White MF J Biol Chem 2000 275 12 9047 9054 10.1074/jbc.275.12.9047 10722755 <p>Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity</p> Um SH Frigerio F Watanabe M Picard F Joaquin M Sticker M Fumagalli S Allegrini PR Kozma SC Auwerx J Thomas G Nature 2004 431 7005 200 205 10.1038/nature02866 15306821 <p>Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling</p> Liberman Z Eldar-Finkelman H J Biol Chem 2005 280 6 4422 4428 10.1074/jbc.M410610200 15574412 <p>A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation</p> Paz K Hemi R LeRoith D Karasik A Elhanany E Kanety H Zick Y J Biol Chem 1997 272 47 29911 29918 10.1074/jbc.272.47.29911 9368067 <p>Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action</p> Aguirre V Werner ED Giraud J Lee YH Shoelson SE White MF J Biol Chem 2002 277 2 1531 1537 10.1074/jbc.M101521200 11606564 <p>Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins</p> Liu YF Paz K Herschkovitz A Alt A Tennenbaum T Sampson SR Ohba M Kuroki T LeRoith D Zick Y J Biol Chem 2001 276 17 14459 14465 11278339 <p>14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain</p> Ogihara T Isobe T Ichimura T Taoka M Funaki M Sakoda H Onishi Y Inukai K Anai M Fukushima Y Kikuchi M Yazaki Y Oka Y Asano T J Biol Chem 1997 272 40 25267 25274 10.1074/jbc.272.40.25267 9312143 <p>Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation</p> Tzatsos A Kandror KV Mol Cell Biol 2006 26 1 63 76 1317643 16354680 10.1128/MCB.26.1.63-76.2006 <p>Interaction of insulin receptor substrate-1 (IRS-1) with phosphatidylinositol 3-kinase: effect of substitution of serine for alanine in potential IRS-1 serine phosphorylation sites</p> Delahaye L Mothe-Satney I Myers MG White MF Van Obberghen E Endocrinology 1998 139 12 4911 4919 10.1210/en.139.12.4911 9832428 <p>Identification of insulin receptor substrate 1 serine/threonine phosphorylation sites using mass spectrometry analysis: regulatory role of serine 1223</p> Luo M Reyna S Wang L Yi Z Carroll C Dong LQ Langlais P Weintraub ST Mandarino LJ Endocrinology 2005 146 10 4410 4416 10.1210/en.2005-0260 16020478 <p>Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2</p> Rui L Fisher TL Thomas J White MF J Biol Chem 2001 276 43 40362 40367 11546773 <p>mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</p> O'Reilly KE Rojo F She QB Solit D Mills GB Smith D Lane H Hofmann F Hicklin DJ Ludwig DL Baselga J Rosen N Cancer Res 2006 66 3 1500 1508 10.1158/0008-5472.CAN-05-2925 16452206 <p>Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition</p> Lee AV Gooch JL Oesterreich S Guler RL Yee D Mol Cell Biol 2000 20 5 1489 1496 85315 10669726 10.1128/MCB.20.5.1489-1496.2000 <p>Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation</p> Greene MW Sakaue H Wang L Alessi DR Roth RA J Biol Chem 2003 278 10 8199 8211 10.1074/jbc.M209153200 12510059 <p>Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1</p> Hiratani K Haruta T Tani A Kawahara J Usui I Kobayashi M Biochem Biophys Res Commun 2005 335 3 836 842 10.1016/j.bbrc.2005.07.152 16099428 <p>Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells</p> Briaud I Dickson LM Lingohr MK McCuaig JF Lawrence JC Rhodes CJ J Biol Chem 2005 280 3 2282 2293 10.1074/jbc.M412179200 15537654 <p>Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies</p> Shah OJ Wang Z Hunter T Curr Biol 2004 14 18 1650 1656 10.1016/j.cub.2004.08.026 15380067 <p>The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins</p> Harrington LS Findlay GM Gray A Tolkacheva T Wigfield S Rebholz H Barnett J Leslie NR Cheng S Shepherd PR Gout I Downes CP Lamb RF J Cell Biol 2004 166 2 213 223 2172316 15249583 10.1083/jcb.200403069 <p>Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation</p> Carlson CJ White MF Rondinone CM Biochem Biophys Res Commun 2004 316 2 533 539 10.1016/j.bbrc.2004.02.082 15020250 <p>Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2</p> Manning BD Logsdon MN Lipovsky AI Abbott D Kwiatkowski DJ Cantley LC Genes Dev 2005 19 15 1773 1778 1182339 16027169 10.1101/gad.1314605 <p>Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis</p> Ozcan U Ozcan L Yilmaz E Duvel K Sahin M Manning BD Hotamisligil GS Mol Cell 2008 29 5 541 551 2361721 18342602 10.1016/j.molcel.2007.12.023 <p>Paradoxical roles of the immune system during cancer development</p> de Visser KE Eichten A Coussens LM Nat Rev Cancer 2006 6 1 24 37 10.1038/nrc1782 16397525 <p>Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro</p> Senzaki H Iwamoto S Ogura E Kiyozuka Y Arita S Kurebayashi J Takada H Hioki K Tsubura A Anticancer Res 1998 18 3A 1621 1627 9673380 <p>Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer</p> Brown NS Bicknell R Breast Cancer Res 2001 3 5 323 327 138696 11597322 10.1186/bcr315 <p>Obesity and prognosis of breast cancer</p> Carmichael AR Obes Rev 2006 7 4 333 340 10.1111/j.1467-789X.2006.00261.x 17038127 <p>Molecular links between obesity and breast cancer</p> Lorincz AM Sukumar S Endocr Relat Cancer 2006 13 2 279 292 10.1677/erc.1.00729 16728564 <p>Regulating insulin signaling and beta-cell function through IRS proteins</p> White MF Can J Physiol Pharmacol 2006 84 7 725 737 10.1139/Y06-008 16998536 <p>Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle</p> Patti ME Virkamaki A Landaker EJ Kahn CR Yki-Jarvinen H Diabetes 1999 48 8 1562 1571 10.2337/diabetes.48.8.1562 10426374 <p>Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells</p> D'Alessandris C Andreozzi F Federici M Cardellini M Brunetti A Ranalli M Del Guerra S Lauro D Del Prato S Marchetti P Lauro R Sesti G Faseb J 2004 18 9 959 961 15059979 <p>Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor</p> Sell C Rubini M Rubin R Liu JP Efstratiadis A Baserga R Proc Natl Acad Sci USA 1993 90 23 11217 11221 47953 8248231 10.1073/pnas.90.23.11217 <p>Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts</p> Sell C Dumenil G Deveaud C Miura M Coppola D DeAngelis T Rubin R Efstratiadis A Baserga R Mol Cell Biol 1994 14 6 3604 3612 358728 8196606 <p>Transforming potential of the insulin receptor substrate 1</p> D'Ambrosio C Keller SR Morrione A Lienhard GE Baserga R Surmacz E Cell Growth Differ 1995 6 5 557 562 7647039 <p>The role of insulin receptor substrate-1 in transformation by v-src</p> Sun H Baserga R J Cell Physiol 2008 215 3 725 732 10.1002/jcp.21352 18064649 <p>Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases</p> Ito T Sasaki Y Wands JR Mol Cell Biol 1996 16 3 943 951 231076 8622697 <p>Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras</p> Cristofanelli B Valentinis B Soddu S Rizzo MG Marchetti A Bossi G Morena AR Dews M Baserga R Sacchi A Oncogene 2000 19 29 3245 3255 10.1038/sj.onc.1203664 10918581 <p>Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules</p> Tanaka S Ito T Wands JR J Biol Chem 1996 271 24 14610 14616 10.1074/jbc.271.24.14610 8662827 <p>Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling</p> DeAngelis T Chen J Wu A Prisco M Baserga R Oncogene 2006 25 1 32 42 16170362 <p>Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors – medulloblastomas</p> Del Valle L Wang JY Lassak A Peruzzi F Croul S Khalili K Reiss K J Neurovirol 2002 8 Suppl 2 138 147 10.1080/13550280290101111 12491166 <p>Adenovirus 5 E1A is responsible for increased expression of insulin receptor substrate 4 in established adenovirus 5-transformed cell lines and interacts with IRS components activating the PI3 kinase/Akt signalling pathway</p> Shimwell NJ Martin A Bruton RK Blackford AN Sedgwick GG Gallimore PH Turnell AS Grand RJ Oncogene 2009 28 5 686 697 10.1038/onc.2008.417 19029952 <p>Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor</p> Prisco M Santini F Baffa R Liu M Drakas R Wu A Baserga R J Biol Chem 2002 277 35 32078 32085 10.1074/jbc.M204658200 12063262 <p>Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen</p> Lassak A Del Valle L Peruzzi F Wang JY Enam S Croul S Khalili K Reiss K J Biol Chem 2002 277 19 17231 17238 10.1074/jbc.M110885200 11877394 <p>Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2</p> Sun H Tu X Prisco M Wu A Casiburi I Baserga R Mol Endocrinol 2003 17 3 472 486 10.1210/me.2002-0276 12554758 <p>Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters</p> Morelli C Garofalo C Sisci D del Rincon S Cascio S Tu X Vecchione A Sauter ER Miller WH Jr Surmacz E Oncogene 2004 23 45 7517 7526 10.1038/sj.onc.1208014 15318176 <p>Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes</p> Wu A Chen J Baserga R Oncogene 2008 27 3 397 403 10.1038/sj.onc.1210636 17700539 <p>Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin</p> Chen J Wu A Sun H Drakas R Garofalo C Cascio S Surmacz E Baserga R J Biol Chem 2005 280 33 29912 29920 10.1074/jbc.M504516200 15967802 <p>Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells</p> Lanzino M Garofalo C Morelli C Le Pera M Casaburi I McPhaul MJ Surmacz E Ando S Sisci D Breast Cancer Res Treat 2009 115 2 297 306 10.1007/s10549-008-0079-1 18521741 <p>Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis</p> Tu X Batta P Innocent N Prisco M Casaburi I Belletti B Baserga R J Biol Chem 2002 277 46 44357 44365 10.1074/jbc.M208001200 12202493 <p>Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination</p> Trojanek J Ho T Del Valle L Nowicki M Wang JY Lassak A Peruzzi F Khalili K Skorski T Reiss K Mol Cell Biol 2003 23 21 7510 7524 207618 14559999 10.1128/MCB.23.21.7510-7524.2003 <p>IRS-1-Rad51 nuclear interaction sensitizes JCV T-antigen positive medulloblastoma cells to genotoxic treatment</p> Trojanek J Ho T Croul S Wang JY Chintapalli J Koptyra M Giordano A Khalili K Reiss K Int J Cancer 2006 119 3 539 548 10.1002/ijc.21828 16572421 <p>Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma</p> Urbanska K Pannizzo P Lassak A Gualco E Surmacz E Croul S Del Valle L Khalili K Reiss K J Cell Physiol 2009 219 2 392 401 2679153 19117011 10.1002/jcp.21683 <p>Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors</p> Buck E Eyzaguirre A Rosenfeld-Franklin M Thomson S Mulvihill M Barr S Brown E O'Connor M Yao Y Pachter J Miglarese M Epstein D Iwata KK Haley JD Gibson NW Ji QS Cancer Res 2008 68 20 8322 8332 10.1158/0008-5472.CAN-07-6720 18922904 <p>Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins</p> Guix M Faber AC Wang SE Olivares MG Song Y Qu S Rinehart C Seidel B Yee D Arteaga CL Engelman JA J Clin Invest 2008 118 7 2609 2619 2430495 18568074